Yuji Sato

机构：JCR Pharmaceuticals (Japan) · ORCID：0000-0002-5185-8643

发表论文 77 篇 · 总被引 856 次 · h-index 15

代表论文

Enzyme Replacement Therapy with Pabinafusp Alfa for Neuronopathic Mucopolysaccharidosis II: An Integrated Analysis of Preclinical and Clinical Data (2021 · International Journal of Molecular Sciences · 被引 45)
Treatment of Neuronopathic Mucopolysaccharidoses with Blood–Brain Barrier-Crossing Enzymes: Clinical Application of Receptor-Mediated Transcytosis (2022 · Pharmaceutics · 被引 31)
Drug delivery for neuronopathic lysosomal storage diseases: evolving roles of the blood brain barrier and cerebrospinal fluid (2022 · Metabolic Brain Disease · 被引 21)
Divergent developmental trajectories in two siblings with neuropathic mucopolysaccharidosis type II (Hunter syndrome) receiving conventional and novel enzyme replacement therapies: A case report (2021 · JIMD Reports · 被引 19)
α-L-iduronidase fused with humanized anti-human transferrin receptor antibody (lepunafusp alfa) for mucopolysaccharidosis type I: A phase 1/2 trial (2024 · Molecular Therapy · 被引 14)
Enzyme Replacement Therapy with Pabinafusp Alfa for Neuronopathic Mucopolysaccharidosis II: an Integrated Analysis of Preclinical and Clinical Data (2021 · Preprints.org · 被引 11)